Polyrizon Ltd Dossier
Qualitative Analysis
Business overview
Polyrizon Ltd. (Nasdaq: PLRZ) is a development-stage biotechnology company headquartered in Ra'anana, Israel. The company specializes in the development of innovative medical device hydrogels delivered in the form of nasal sprays. These sprays form a thin, hydrogel-based shield containment barrier in the nasal cavity, functioning as a "biological mask" to protect against viruses, allergens, and other airborne pathogens. Polyrizon's proprietary platform technologies include Capture & Contain™ (C&C), which is designed to trap and neutralize allergens and viruses, and Trap & Target™ (T&T), which is focused on the intranasal delivery of active pharmaceutical ingredients (APIs). Its lead product candidate is NASARIX™ (PL-14), an intranasal allergy blocker.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Advancing the lead Capture and Contain (C&C) hydrogel allergy blocker candidate into human clinical trials. The company has secured three major U.S. clinical sites and entered into agreements with European medical centers to characterize nasal residence time and support the FDA regulatory pathway.
Expected impact: Establish clinical proof-of-concept, safety, and efficacy to support a future FDA 510(k) clearance application.
Exploring strategic investment and acquisition opportunities in non-biotech sectors, specifically aviation, defense, and artificial intelligence, to leverage the company's cash position and establish revenue-generating operations.
Expected impact: Transition the company from a pre-revenue development-stage biotech into a diversified holding entity with active, revenue-generating operations.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Polyrizon signed a non-binding MOU to acquire a 51% stake in Arrow Aviation, a private aviation services provider with $19 million in annual revenue and $3 million in adjusted EBITDA. The exclusivity period was extended to June 30, 2026.
Terms: Cash investment of NIS 18,000,000 (approximately $5.8 million) for a 51% stake, with mutual call/put options for the remaining 49% after two years.
Polyrizon signed a non-binding MOU to acquire up to a 20% stake in Colugo Systems, an Israeli developer of advanced eVTOL drone systems serving the Israel Defense Forces and first responders.
Terms: Aggregate purchase price of up to $6 million, payable in cash or Polyrizon ordinary shares.
Out-licensing of SciSparc's SCI-160 program for pain treatment, granting Polyrizon exclusive global rights to develop and sublicense the cannabinoid-based assets.
Terms: SciSparc received Polyrizon securities valued at $3 million and is entitled to up to $3.32 million in cash milestone payments plus royalties.
Development of a tailored intranasal delivery system using Polyrizon's Trap & Target (T&T) platform for NurExone's ExoTherapy targeting traumatic spinal cord injuries.
Terms: NurExone pays formulation development costs of approximately $220,000, plus milestone-based development fees of up to $3.35 million and a 35% royalty fee on sublicensed product sales.